Contact: t.hagemann@qmul.ac.uk

Professional interests

Dr Hagemann specialized in Haematology and Oncology and in General Internal Medicine. He gained his MD/PhD at the Medical Faculty, University of Göttingen, Germany during which time he developed research interests in tumour-associated macrophages (TAM) and the tumour microenvironment. During his early post-doctoral studies Dr Hagemann developed an in vitro co-culture system to study the phenotype of TAM. With the award of post-doctoral fellowships from the German Research Foundation and a Marie Curie Fellowship Dr Hagemann continued his studies at the Centre for Translational Oncology at Barts and The London, Queen Mary's School of Medicine and Dentistry under Prof Fran Balkwill, where he gained training in the use of molecular genetics to study the regulation of the TAM phenotype. These studies focussed on the role of the TNF-a signalling in the biology of the tumour microenvironment, especially the macrophage; using transgenic models and tissue specific gene targeting to establish the specific role of TNF-a for maintenance of the TAM phenotype. In 2007 he gained an MRC Clinician Scientist Award and became a Lecturer at the Institute of Cancer and established his Tumour Microenvironment Group in the Centre for Cancer & Inflammation . The major research focus of the group is to understand the fundamental mechanisms by which TNF-α signalling promotes cancer; with particular reference to the role of macrophages and their phenotype in carcinogenesis.

Research Team:

Dr Robin Soper	Postdoctoral Research Assistant
Dr Monica Escorcio-Correia	Postdoctoral Research Assistant
Maud Bossard	PhD Student
Anne Schultheiss	Research Assistant
Simon Hallam	PhD Student
Juliana Candido	PhD Student
Dr Eleni Maniati	Postdoctoral Research Assistant
Nia Emami	Research Assistant

 

Funding:

CR-UK Discovery committee grant, £200,000 (over 2 years) "Generation of antibodies against the chemokine CXCL12 for cancer therapy"

PhD studentship St. Bartholomew's and the London School of Medicine and Dentistry, Queen Mary College, University of London, 2008-2011 £80,000

CR-UK Programme Grant (with Prof F. Balkwill) £346,330 pa for 5 years"Targeting Cancer-Related Inflammation"

CR-UK Programme Grant (with Prof B. Vanhaesebroeck), £491,485 pa for 5 years "Class IA PI 3-kinase isoforms in oncogenic signaling"

CR-UK project grant 2009-2011 £226,210 "Cancer-related inflammation: immune tolerance and tumour progression mediated via paracrine TNF-α"

MRC CASE PhD Studentship, industrial collaboration with AstraZeneca 2009-2013 £130,750

Cancer Research Committee of St. Bartholomew's Hospital 2008-2009, £ 8000 Ptch/Shh signalling: a double-edged sword in ovarian cancer”

Best Poster Award MRC Oncology & Cancer Showcase 2007

MRC Clinician Scientist Fellowship 2007-2011 £896,479 "Re-educating’ tumour-associated macrophages"

St. Bartholomew's and The Royal London Hospital Charitable Foundation RAB Project Grant 2007-2009 £99,365 "Investigation of the role of IκB kinase (IKK) β and hypoxia in maintaining the phenotype of tumour associated macrophages"

FP6 European Union Marie Curie Fellowship 2005-2007 £107,316

Cancer Research Committee of St. Bartholomew's Hospital 2006-2007 £7760 "Identification of molecular determinants involved in alternative activation of ovarian cancer-associated macrophages"

Cancer Research Committee of St. Bartholomew's Hospital 2004-2005 £7500 "The role of the leucocyte infiltrate in cancer, especially the interactions between tumour cells and macrophages"

German Research Foundation Postdoctoral Fellowship 2004-2005 £40,732.

Recent Publications:

• Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty S, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T. The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009;in press.
• Hagemann T, Binder C, Sperling S, Schulz M, Pukrop T, Grimshaw MJ, Ehrenreich H. Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis. Mol Cancer Ther 2009;8(8):2452-60.
• Hallam S, Escorcio-Correia M, Soper S, Schultheiss A, Hagemann T. Activated macrophages in the tumour microenvironment - dancing to the tune of TLR and NF-κB. J Pathol 2009;219(2):143-52.
• Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis C. Regulation of Macrophage Function in Tumors: the Multifaceted Role of NF-kB. Blood 2009;113:3139-46.
  
• Hagemann T, Lawrence T, McNeish I, Kulbe H, Thompson RG, Charles KA, Robinson SC, Balkwill FR. "Re-educating" tumor-associated macrophages by targeting NF-κB signaling. J Exp Med 2008;205:1261-8.
  
• Hagemann T, Balkwill F, Lawrence T. Inflammation and Cancer: A Double-Edged Sword. Cancer Cell 2007;12:300-1.
• Lawrence T, Hagemann T, Balkwill F. Sex, Cytokines, and Cancer. Science 2007;317(5834), 51-2.
• Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR. Ovarian Cancer Cell Derived MIF Enhances Tumor Growth, Progression and Angiogenesis. Mol Cancer Ther 2007;6:1993-2002.
• Szlosarek PW, Grimshaw MJ, Wilbanks GD, Hagemann T, Wilson JL, Burke F, Stamp G, Balkwill FR. Aberrant regulation of argininosuccinate synthetase by TNF-α in human epithelial ovarian cancer. Int J Cancer 2007;121:2760-5.
• Hagemann T, Bozanovic T, Hooper S, Ljubic A, Slettenaar VIF, Wilson JL, Singh N, Gayther SA, Shepherd JH, Van Trappen PO. Molecular profiling of cervical cancer progression. British Journal of Cancer 2007;96:321-8.
• Kulbe H, Thompson R, Wilson J, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F. The inflammatory cytokine TNF-α generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007;67:585-92.
• Li NF, Broad S, Dafou D, Lu YJ , Yang JS, Hagemann T, Watson R Wilbanks G, Balkwill F, Gayther S. hTERT Immortalised Human Ovarian Surface Epithelial Cells Maintain Functional pRb and p53 Expression. Cell Proliferation 2007;40(5):780-9.
• Hagemann T, Wilson J, Burke, F, Kulbe H, Li, NF, Plüddemann, A, Charles K, Gordon, S, Balkwill FR. Ovarian cancer cells polarize macrophages towards a tumor-associated phenotype. J Immunol 2006;176:5023-32.
• Pukrop T, Klemm F, Hagemann Th, Gradl D, Schulz M, Trümper L, Binder C. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. PNAS 2006;103:5454-9.
• Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson J. The inflammatory cytokine TNF-α regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 2006;65:10355-62.
• Schüttrumpf S, Binder L, Hagemann T, Berkovic D, Trümper L, Binder C. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis 2006;43:468-73.
• Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR. Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK. J Immunol 2005;175:1197-1205.
• Hagemann T and Balkwill FR. MIFed about cancer? Gastroenterology 2005;129:1785-6.

• Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ. Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA and Cell Biology 2005;24:777-87.

<< Return to staff list